Rhetoric Meets Reality: A Timeline Of Trump's First 100 Days
Executive Summary
President Trump is empty-handed on health care victories so far, as initial health reform repeal efforts collapsed and the shock value of drug pricing tweets wore off. But some actions may evolve into biopharma impact further down the road.
You may also be interested in...
Gottlieb Advances, But FDA's Future Seems Increasingly Partisan
Senate committee votes to send the FDA Commissioner nominee to the Senate floor, but with only two Democratic votes.
Trump’s Next 1,000 Days: Advice For The Pharma C-suite
Although signs suggest the Trump Administration is moving back to the establishment center, biopharma’s knowledge elites remain in the populists’ crosshairs. It’s vital to change the narrative on medicines and markets. In this brief opinion piece In Vivo provides seven ways for the C-suite to do just that.
FDA User Fee Bills: Is It Possible For Reauthorization To Be Too Clean?
First draft of user fee omnibus bill is about as 'clean' as a bill can be – free of the policy riders that have always been attached to US FDA funding legislation in past cycles. That is good news for industry, which is eager to see the program reauthorized with as little drama as possible, but could the bill actually be too clean?